fighterpilot, you might want to read the management discussion in GERNs last SEC filed quarterly report as they discuss this to some extent there based on reports Tefferi gave to GERN. And they say that, at that time, more than 50 patients were enrolled in trials, including trials of MF, AML and MDS. Apparently, the first three cohorts of 11 patients each were enrolled in MF trials, but GERN says that Tefferi is testing Imetelstat on patients with AML and MDS, which are two additional and more serious indications. Irishtrader has posted that she knows of 8 AML patients, half of which have had a "response" to Imetelstat, and one of which is almost responding with a CR. This is extremely bullish information for GERN and once Tefferi writes this part up, it should have a major value added impact to what has already been disclosed about responses in MF patients. I don't know, but assume that some or all of these AML and MDS patients may have begun with MF that progressed into AML or MDS.
Your husband has an amazing wife, that would go to such exhausting effort to study his disease and find the best Dr. to treat him. In your research you ended here, just like so many of us have. The science of telomerase has a way of doing that